

**COMMONWEALTH OF KENTUCKY  
CABINET FOR HEALTH AND FAMILY SERVICES  
DEPARTMENT FOR MEDICAID SERVICES  
PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING**

**NOTE: This special called meeting will be held virtually via Zoom webinar.**

Thursday, March 17, 2022  
1:00 P.M. to 4:00 P.M. (Eastern)

**Access Information**

Smartphone/Web	Dial-In
<a href="https://magellanhealth.zoom.us/j/99337766415">https://magellanhealth.zoom.us/j/99337766415</a> Webinar ID: 993 3776 6415 Password: 425341	+1 312 626 6799 (US Toll) OR +1 646 558 8656 (US Toll) Webinar ID: 993 3776 6415 Passcode: 425341

**AGENDA**

- I. Call to Order and Welcome**
- II. Executive Session (upon request)**
- III. Old Business**
  - a. Approval of November 2021 Meeting Minutes
- IV. New Business**
  - a. New Products to Market to be reviewed as single products:
    - i. Qulipta™ (Anti-Migraine: CGRP Inhibitors)
    - ii. Lybalvi™ (Second-Generation Antipsychotics)
    - iii. Winlevi® (Topical Acne Agents)
    - iv. Azstarys™ (Stimulants and Related Agents)
    - v. Bylvay™ (Bile Salts)
    - vi. Livmarli™ (Bile Salts)
    - vii. Opzelura™ (Immunomodulators, Atopic Dermatitis)
    - viii. Rezurock™ (Immunosuppressants)
    - ix. Tyrvaya™ (Ophthalmic Immunomodulators)
    - x. Skytrofa™ (Growth Hormones)
    - xi. Livtencity™ (Non-PDL)
    - xii. Exkivity™ (Non-PDL: Oral Oncology, Lung)
    - xiii. Scemblix® (Non-PDL: Oral Oncology)
    - xiv. Welireg® (Non-PDL: Oral Oncology)
  - b. Existing products to be reviewed as single products:
    - i. Tukysa® (Non-PDL: Oral Oncology, Breast)
    - ii. Pemazyre™ (Non-PDL: Oral Oncology)
    - iii. Qinlock™ (Non-PDL: Oral Oncology)
- I. Therapeutic Classes with Recommended Changes**
  - a. Antibiotics: Inhaled
  - b. Antibiotics: Vaginal
  - c. Antiretrovirals: HIV/AIDS

- d. Antibiotics: Oxazolidinones
- e. Antibiotics: Tetracyclines
- f. Intranasal Corticosteroids

**V. Consent Agenda**

- a. The following therapeutic classes have no changes recommended and may be voted on as a group under a consent agenda:

<ul style="list-style-type: none"> <li>• Antibiotics: Cephalosporins 1st Generation</li> <li>• Antibiotics: Cephalosporins 2nd Generation</li> <li>• Antibiotics: Cephalosporins 3rd Generation</li> <li>• Antibiotics: Gastrointestinal (GI)</li> <li>• Antibiotics: Macrolides/Ketolides</li> <li>• Antibiotics: Penicillins</li> <li>• Antibiotics: Pleuromutilins</li> <li>• Antibiotics: Quinolones</li> <li>• Antibiotics: Sulfonamides, Folate Antagonists</li> <li>• Antifungals: Oral</li> <li>• Anti-Infectives: Hepatitis B</li> <li>• Antivirals: Herpes</li> <li>• Antivirals: Influenza</li> </ul>	<ul style="list-style-type: none"> <li>• Beta Agonists: Combination Products</li> <li>• COPD Agents</li> <li>• Hepatitis C: Direct-Acting Antiviral Agents</li> <li>• Hepatitis C: Interferons</li> <li>• Hepatitis C: Ribavirins</li> <li>• Inhaled Corticosteroids</li> <li>• Intranasal Antihistamines and Anticholinergics</li> <li>• Leukotriene Modifiers</li> <li>• Long-Acting Beta2 Adrenergic Agonists</li> <li>• Minimally Sedating Antihistamines</li> <li>• Self-Injectable Epinephrine</li> <li>• Short-Acting Beta2 Adrenergic Agonists</li> </ul>
--	---

**V. Adjournment**

- a. Schedule of Upcoming Meetings
  - i. **May 19, 2022**
  - ii. **July 21, 2022**

To view the most current Preferred Drug List (PDL) and Prior Authorization (PA) criteria please go to <https://kyportal.magellanmedicaid.com/provider/public/home.xhtml>.

**PUBLIC SPEAKERS:** If you would like to speak during the public session, please complete the Speaker Request Form located on the Committees/P&T tab of the Kentucky specific Magellan Medicaid Administration web portal at: <https://kyportal.magellanmedicaid.com/provider/public/documents.xhtml>.